BRAF and melanoma: Nonetheless, patients with melanoma often fail to respond to BRAFi/MEKi despite harboring V600 BRAF mutations, and in some cases, responses have been noted to BRAFi monotherapy despite progression on a prior course of treatment with a different BRAFi (2).